These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2172826)

  • 21. [Opiates and their antagonists].
    Langwiński R
    Pol Tyg Lek; 1983 Dec 19-26; 38(51-52):1625-9. PubMed ID: 6089154
    [No Abstract]   [Full Text] [Related]  

  • 22. Stereochemical influences upon the opioid ligand activities of 4-alkyl-4-arylpiperidine derivatives.
    Casy AF; Dewar GH; al Deeb OA
    Chirality; 1989; 1(3):202-8. PubMed ID: 2561991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-endorphin-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
    Silva RM; Hadjimarkou MM; Rossi GC; Pasternak GW; Bodnar RJ
    J Pharmacol Exp Ther; 2001 May; 297(2):590-6. PubMed ID: 11303047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.
    Emmerson PJ; McKinzie JH; Surface PL; Suter TM; Mitch CH; Statnick MA
    Eur J Pharmacol; 2004 Jun; 494(2-3):121-30. PubMed ID: 15212965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1989 Annual Report, evaluation of new compounds for opioid activity.
    Woods JH; Medzihradsky F; Smith CB; Winger GD; France CP
    NIDA Res Monogr; 1989; 95():632-79. PubMed ID: 2561858
    [No Abstract]   [Full Text] [Related]  

  • 26. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperalgesia produced by intrathecal opioid antagonists depends on receptor selectivity and noxious stimulus.
    Pilcher CW; Browne JL
    NIDA Res Monogr; 1986; 75():469-72. PubMed ID: 2828994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational analysis of opioid receptor-selective peptides using nuclear magnetic resonance and theoretical calculations.
    Hruby VJ; Prakash O; Kazmierski W; Gehrig C; Matsunaga TO
    NIDA Res Monogr; 1991; 112():198-217. PubMed ID: 1661378
    [No Abstract]   [Full Text] [Related]  

  • 30. Recent advances in selective opioid receptor agonists and antagonists.
    Eguchi M
    Med Res Rev; 2004 Mar; 24(2):182-212. PubMed ID: 14705168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro evaluation of a novel, non-competitive opioid receptor antagonist.
    Davis P; Kramer T; Burks T
    Proc West Pharmacol Soc; 1989; 32():163-6. PubMed ID: 2550940
    [No Abstract]   [Full Text] [Related]  

  • 32. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
    Liao S; Alfaro-Lopez J; Shenderovich MD; Hosohata K; Lin J; Li X; Stropova D; Davis P; Jernigan KA; Porreca F; Yamamura HI; Hruby VJ
    J Med Chem; 1998 Nov; 41(24):4767-76. PubMed ID: 9822547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opiate receptor revisited.
    Snyder SH
    Anesthesiology; 2007 Oct; 107(4):659-61. PubMed ID: 17893463
    [No Abstract]   [Full Text] [Related]  

  • 34. Multiple opioid receptor systems in brain and spinal cord: Part 2.
    Yaksh TL
    Eur J Anaesthesiol; 1984 Sep; 1(3):201-43. PubMed ID: 6152614
    [No Abstract]   [Full Text] [Related]  

  • 35. [Use of opiate receptor antagonists and peptidase inhibitors for studying central morphinomimetic peptidergic systems].
    Malfroy B
    Ann Endocrinol (Paris); 1983; 44(5):335-7. PubMed ID: 6326657
    [No Abstract]   [Full Text] [Related]  

  • 36. Opioid pharmacology a'la mode.
    Takemori AE
    NIDA Res Monogr; 1992; 119():21-6. PubMed ID: 1331795
    [No Abstract]   [Full Text] [Related]  

  • 37. One- and two-receptor models of opioid drug action.
    Gero A
    Life Sci; 1985 Mar; 36(11):1021-4. PubMed ID: 2983162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
    Katavic PL; Lamb K; Navarro H; Prisinzano TE
    J Nat Prod; 2007 Aug; 70(8):1278-82. PubMed ID: 17685652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opiate receptors and their definition by antagonists.
    Yaksh TL; Howe JR
    Anesthesiology; 1982 Apr; 56(4):246-9. PubMed ID: 6278990
    [No Abstract]   [Full Text] [Related]  

  • 40. Opioid antagonist-induced upregulation and functional supersensitivity.
    Yoburn BC
    Rev Clin Basic Pharm; 1988; 7(1-4):109-28. PubMed ID: 2854647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.